Cancer is notoriously complex. It doesn’t follow a predictable playbook, and even with the most advanced diagnostics and innovative drugs, treatments can miss the mark. For many patients, a tumor may qualify for a certain therapy, but that doesn’t guarantee the treatment will work. This disconnect highlights two major challenges in oncology today: overtreatment and undertreatment. Beyond inflating healthcare costs, they put patients at risk of ineffective care and unnecessary side effects.
Enter PredictionStar™—a bold solution aimed at closing that gap. Instead of relying solely on traditional markers of treatment eligibility and intensity, PredictionStar™ factors in how tumors are likely to respond, offering actionable, personalized insights. And at the helm of this transformation is Wolfgang Hackl, CEO of OncoGenomX.
From Oncology Expert to Visionary Leader
Wolfgang Hackl’s career spans over 20 years in oncology, with deep expertise in cancer drug development. His track record includes contributing to over 30 R&D projects—two-thirds of which reached clinical trials, and five secured FDA approval. Yet, it wasn’t accolades that defined his mission; it was a realization of a critical gap in cancer care.
“In today’s system, we provide oncologists with markers that guide which treatments and at what intensity they apply,” Hackl explains. “But we can’t predict whether a treatment will actually be effective until the results come back months later.” This insight set him on a new path—shifting from drug development to crafting tools that empower smarter treatment decisions.
The Birth of OncoGenomX and PredictionStar™
Hackl’s solution tackles two major blind spots in oncology: the inability of existing tests to reliably predict therapeutic response and the reductionist approach of targeting cancer drivers without considering the unique biology of tumor response.
PredictionStar™ is a therapy decision support system powered by AI, integrating clinical, biological, phenotypic, and genotypic data into a predictive model. Instead of the outdated trial-and-error method, it identifies anti-cancer agents likely to yield tumor response and durable control. The goal? Smarter combinations of treatments tailored to each tumor.
“PredictionStar™ bridges the critical gap between eligibility markers and actual treatment efficacy,” Hackl says. His team’s breakthrough lies in combining data analysis with biological cause-effect understanding, ensuring predictions are both powerful and interpretable by clinicians.
Real-World Impact: Cutting Overtreatment
Overtreatment in breast cancer is driven by fear—of legal repercussions, patient anxiety, and the desire for absolute certainty. Yet, studies reveal that the contemporary approach risks 56% of patients receiving suboptimal combination therapy.
PredictionStar™ flips that narrative. By guiding first- and second-line treatment combinations, it reduces the risk of suboptimal care from 56% to just 15%. And in doing so, it cuts treatment costs by over threefold.
“Our system empowers oncologists to select drug combinations each highly likely to yield tumor response, maximizing success while minimizing toxicity,” Hackl emphasizes.
A Leadership Style Rooted in Collaboration and Vision
Hackl leads with a clear framework: Unified Vision, Collaborative Structures, Culture of Respect, and Alignment. His management philosophy revolves around empowering interdisciplinary teams—oncologists, researchers, data scientists, and business leaders—to innovate together, without the traditional silos slowing progress.
At the core of OncoGenomX’s success are Hackl’s five pillars of leadership: visionary thinking, authentic communication, agility, empowerment, and resilient optimism. This foundation fuels a culture where challenges turn into opportunities.
Navigating Complexity with Precision
One of the toughest hurdles? Integrating diverse datasets into a cohesive model. Hackl explains, “It’s not just about collecting data; it’s about understanding which biomarkers reflect the functional state of the mechanisms driving tumor response.”
OncoGenomX’s hybrid approach—melding machine learning with rule-based validation and clinician involvement—strikes the perfect balance between predictive power and clinical interpretability. No black-box solutions here, just clear, actionable insights doctors can trust.
Looking Ahead: Scaling Impact Globally
Wolfgang Hackl’s vision extends beyond breast cancer. OncoGenomX is building a pan-cancer intelligence platform designed to tackle lung, prostate, colon, and ovarian cancers. The goal is to transform PredictionStar™ into a universal tool that empowers precision oncology worldwide.
“We aim to build international partnerships across health systems, diagnostics, pharma, and health IT, making personalized cancer care accessible at scale,” Hackl states.
Driven by Purpose
Hackl’s leadership is deeply personal. He’s witnessed firsthand how one-size-fits-all treatments often fall short, and his mission goes beyond technology—it’s about reducing suffering and delivering hope grounded in biology.
His advice for aspiring healthcare visionaries? “Start with a real-world problem. Stay close to patients and providers. Be bold, but collaborate. Innovation in healthcare is a team sport.”
A New Era of Cancer Care
Under Wolfgang Hackl’s leadership, OncoGenomX is redefining the future of oncology. By turning predictive insights into clinical action, the company is making personalized, precise cancer treatment a reality.
In a world where every tumor tells a unique story, Hackl’s vision is clear: treatment decisions should reflect that individuality, not population-based probabilities. With science, leadership, and empathy working in concert, the future of cancer care is brighter than ever.